Business
-
Verona Pharma has announced that Kenneth Newman, a former Acton Pharmaceuticals CMO and former Boehringer Ingelheim VP, Medical Affairs, will become Verona’s Chief Medical Officer as of January 1. At Acton, Newman headed up clinical… Read more . . .
-
Novartis has reportedly sued Cipla in the Delhi High Court for infringing patents related to Novartis’s Onbrez Breezhaler indacaterol DPI (Arcapta Neohaler). Cipla began marketing a generic indacaterol DPI called “Unibrez” in October; after losing… Read more . . .
-
Lightlake Therapeutics has agreed to license its intranasal naloxone for opioid overdose reversal to Adapt Pharma for possible development and sales milestones of more than $55 million, plus royalties, the company said. Lightlake recently announced… Read more . . .
-
GSK has announced that it will change the color of the Relvar Ellipta fluticasone/vilanterol DPI starting in January 2015. The company said that it will remove the color blue from the inhaler and its packaging… Read more . . .
-
Cystic Fibrosis Foundation Therapeutics (CFFT), a nonprofit associated with the Cystic Fibrosis Foundation, has announced that it will provide Shire with up to $15 million for development of an aerosol messenger RNA therapy designed to… Read more . . .
-
Pfizer has launched Novartis’ Ultibro Breezhaler indacaterol/glycopyrronium DPI for the treatment of COPD in the UK, the company said. Ultibro Breezhaler was approved in Europe in September 2013. In September 2014, Pfizer announced that it… Read more . . .
-
Meda Pharmaceuticals and Cipla have filed suit against Apotex in the Delaware Federal District Court, claiming that Apotex’s submission of an ANDA for a generic version of Dymista azelastine HCl/fluticasone propionate nasal spray violates patents… Read more . . .
-
Avanir Pharmaceuticals, which just received a complete response letter from the FDA for its AVP-825 intranasal sumatriptan powder, has announced that it will be acquired by Otsuka Pharmaceutical for approximately $3.5 billion. Avanir will become… Read more . . .
-
Skyepharma has announced that Mundipharma has launched the Flutiform fluticasone/formoterol MDI for the treatment of asthma in Spain, triggering a milestone payment of €2.0 million. In addition, Mundipharma marketing partner Zambon Italia has now launched… Read more . . .
-
Endo International has acquired exclusive US and Mexican rights to Trimel BioPharma’s Natesto testosterone nasal gel, which was approved by the the FDA in May 2014 as a replacement treatment for men with low levels… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland